Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trialDaniel D. Mikol, Bernard M.J. Uitdehaag, Bettina Stubinski et al.|The Lancet Neurology|2008Cited by 484
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patientsTatiana Plavina, Bruce Cree, Ivan Nestorov et al.|Neurology|2017Cited by 92
ATON: Results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritisRobert C. Sergott, Johan van Beek, Jeffrey L. Bennett et al.|Journal of the Neurological Sciences|2015Cited by 81